Better by design: a regulatory perspective on rationalizing combination selection and development

Roisin McGuigan, Editor, BioInsights, speaks to Elaine Chang, US Food and Drug Administration (FDA), Office of Oncologic Diseases.

Elaine Chang is a medical oncologist at the US Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Office of Oncologic Diseases. She completed her hematology/oncology fellowship at Baylor College of Medicine and joined FDA in 2018. She is serving as one of the Acting Team Leads for the Genitourinary Malignancies Team in Division of Oncology 1. Her research has focused on novel endpoints in renal, bladder, and prostate cancer. She has an interest in facilitating multi-stakeholder discussions on clinical trial design and rational drug development strategies that address unmet needs.

Please enter your email to access content Read now